HOME > REGULATORY
REGULATORY
- JMACCT Revamps Database of Clinical Trial Institutions; Details Now Available Online
February 27, 2013
- MHLW Launches HQ to Promote Health and Medical Strategy
February 27, 2013
- Doctors' Average Monthly Wage Reaches 789,300 Yen in 2012, MHLW Survey Shows
February 25, 2013
- Govt Launches New Office of Health and Medical Strategy
February 25, 2013
- Ruling Parties’ Commission on Reduced Consumption Tax Rate System to Issue Interim Report This Summer
February 22, 2013
- MHLW Plans to Revise Ordinance within 2 to 3 Years to Allow Electronic Prescribing
February 22, 2013
- About 60% of Prefectures Won't Set Generic Share Targets in Medical Expenditure Optimization Plans
February 22, 2013
- MHLW to Examine Online OTC Drug Sales after Top Court Ruling
February 22, 2013
- EAD Director Kamata Calls for Early Price Settlements at Municipal Hospitals
February 21, 2013
- MHLW Eager to Submit Bill to Amend PAL to Diet by Summer, Councilor Hirayama Says
February 21, 2013
- Tokyo’s Katsushika Ward Allies with Wholesalers in Drug Procurement during Disasters
February 21, 2013
- Private-sector Members of Industrial Competitiveness Council Divided on Measures to Strengthen Innovation
February 20, 2013
- Prof. Morishita Calls for New Pricing System for Innovative Drugs; Doubling Prices Yielded by Current Cost Calculation Method
February 19, 2013
- 25 Companies Receive Approval for Generic Loxonin Tape, 11 Companies for Generic Calblock
February 19, 2013
- Regulatory Reform Council’s Priority Areas Include Health, Medicine; Discussion Topics to Be Set by Feb.-End
February 18, 2013
- Notification on Clinical Trial Documents and Records Cancels Previous Rules on Paper-Based “Original Documents and Duplicate Copies”
February 18, 2013
- MHLW Panel Kicks Off Discussion on New Rules for Online Drug Sales, Won’t Cover Ethical Products
February 15, 2013
- MHLW to Set Up “Central Liaison Council” this Fiscal Year to Unify Criteria for Reviewing Medical Bills
February 15, 2013
- CSIMC OKs NHI Price Listing of 17 APIs; Peak Sales of 34 Billion Yen Projected for Eliquis
February 14, 2013
- EAD Director Kamata Encourages Generic Makers to Develop Overseas Operations
February 13, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…